JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M004484200 on June 19, 2000

J. Biol. Chem., Vol. 275, Issue 34, 25920-25925, August 25, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/34/25920    most recent
M004484200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Avvakumov, G. V.
Right arrow Articles by Hammond, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avvakumov, G. V.
Right arrow Articles by Hammond, G. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Steroid-binding Specificity of Human Sex Hormone-binding Globulin Is Influenced by Occupancy of a Zinc-binding Site*

George V. AvvakumovDagger , Yves A. Muller§, and Geoffrey L. HammondDagger

From the Dagger  Departments of Obstetrics & Gynecology and Pharmacology & Toxicology and Medical Research Council Group in Fetal and Neonatal Health and Development, University of Western Ontario, London, Ontario N6A 4L6, Canada and § Forschungsgruppe Kristallographie, Max-Delbrück-Center for Molecular Medicine, Robert-Roessle-Strasse 10, D-13092 Berlin, Germany

Received for publication, May 24, 2000, and in revised form, June 15, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

One calcium-binding site (site I) and a second poorly defined metal-binding site (site II) have been observed previously within the amino-terminal laminin G-like domain (G domain) of human sex hormone-binding globulin (SHBG). By soaking crystals of this structure in 2.5 mM ZnCl2, site II and a new metal-binding site (site III) were found to bind Zn2+. Site II is located close to the steroid-binding site, and Zn2+ is coordinated by the side chains of His83 and His136 and the carboxylate group of Asp65. In this site, Zn2+ prevents Asp65 from interacting with the steroid 17beta -hydroxy group and alters the conformations of His83 and His136, as well as a disordered region over the steroid-binding site. Site III is formed by the side chains of His101 and the carboxylate group of Asp117, and the distance between them (2.7 Å) is increased to 3.7 Å in the presence of Zn2+. The affinity of SHBG for estradiol is reduced in the presence of 0.1-1 mM Zn2+, whereas its affinity for androgens is unchanged, and chemically-related metal ions (Cd2+ and Hg2+) have similar but less pronounced effects. This is not observed when Zn2+ coordination at site II is modified by substituting Gln for His136. An alteration in the steroid-binding specificity of human SHBG by Zn2+ occupancy of site II may be relevant in male reproductive tissues where zinc concentrations are very high.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasma sex hormone-binding globulin (SHBG)1 is a homodimeric glycoprotein produced by hepatocytes (1). It transports sex steroids in the blood and regulates their access to target cells (1, 2). The transcription unit responsible for plasma SHBG production by the liver is also expressed in rat Sertoli cells (3), and the protein product is known as the androgen-binding protein (ABP). Testicular ABP has exactly the same primary structure and steroid-binding properties as plasma SHBG and is thought to control androgen-dependent sperm maturation in the male reproductive tract (1, 3). Human SHBG and rat ABP comprise two laminin G-like domains (4) and share sequence similarity with the carboxyl-terminal regions of numerous extracellular proteins with diverse functions, including the blood coagulation co-factor, protein S; the growth factor, Gas 6; and several matrix-associated proteins (4). There is reason to suspect that the structural relationship between these proteins is functionally significant because their SHBG-like domains comprise binding sites for several members of an orphan tyrosine-kinase receptor superfamily (5). In addition, several groups have advanced the hypothesis that SHBG interacts with a plasma membrane receptor that contributes to steroid signaling pathways (6), but the biological impact of these interactions remains obscure.

Studies of human and rabbit SHBG with the luminescent lanthanide, terbium, have indicated that each dimer of SHBG contains four metal-binding sites (7). At least one of these sites was assumed to bind calcium because calcium ions stabilize the steroid-binding activity of the purified protein (8) and enhance SHBG dimer formation (9). A calcium-binding site was recently located within the amino-terminal laminin G-like domain (G domain) of human SHBG, which was complexed with steroid ligand, but it is at least 20 Å from the closest steroid atom and is not close to the proposed dimer interface (10). In addition, a strong difference density peak was observed at the end of strand beta 6 in this crystal structure but was unsatisfactorily modeled as another calcium-binding site because of multiple conformations of the coordinating side chains (10).

The location of this second metal-binding site was intriguing because it lies in the vicinity of a disordered region in the crystal structure of the amino-terminal G domain of human SHBG, which loops over the steroid-binding site (10). Moreover, amino acids within this particular region of human SHBG can be affinity labeled with reactive groups attached to steroid ligands (11), and their substitution with residues in the corresponding position of rat ABP results in altered steroid-binding specificity (9). The possibility that the second metal-binding site might have been partially occupied by zinc in our original crystal structure (10) was considered because histidine residues are present at the end of strand beta 6, as well as in the disordered loop over the steroid-binding site. Furthermore, the histidine at the end of strand beta 6 is next to Asn82, which forms a hydrogen bond with the hydroxyl-group at C17 in the steroid ring D (10). This suggested to us that coordination of a metal ion, such as Zn2+, in this position might influence the steroid-binding activity of SHBG. There are large amounts of zinc in the male reproductive tract, especially in locations where SHBG may play a role in regulating the activities of sex-steroids, such as the prostate (12, 13). Therefore, we set out to determine if a metal-binding site exists in this region of human SHBG and if its occupancy by zinc influences the steroid-binding specificity of the protein.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Crystallographic Analysis of Zinc-soaked SHBG Crystals-- Crystals of the amino-terminal G domain of SHBG were obtained as described (14). Single crystals were harvested from the crystallization droplets and soaked for three days in a "soaking solution" (5% polyethylene glycol 400 and 20% isopropanol in 100 mM HEPES buffer, pH 7.5, containing 1 mM CaCl2, 1.5 µM 5alpha -dihydrotestosterone (DHT), and 2.5 mM ZnCl2). Before flash cooling to prevent ice formation, the crystals were transferred for 5 min into the soaking solution to which 20% (v/v) glycerol had been added. A data set to 1.7 Å resolution was collected on beamline ID14 at the ESRF synchrotron in Grenoble at a wavelength of 0.933 Å using a MarCCD detector. A total of 120 exposures recorded in three different passes, with one and two degree oscillation steps each and aiming at different resolution shells, yielded a 96.3% complete data set with a merging R-factor of 6.5% in program XDS (15). When keeping the Friedel pairs unmerged, the data set is still 95.3% complete (Table I).

The zinc-soaked crystals of SHBG are of space group R32 with cell axes a = 104.02 Å and c = 84.71 Å and are isomorphous to the crystals of the previously reported (10) SHBG model (Protein Data Bank accession number 1d2s). Structure refinement was straightforward, starting with a model consisting of only the polypeptide chain and the bound DHT, and alternating between rounds of visual inspection with program O (16) and refinement with program REFMAC (17). Initial Sigmaa-weighted difference density maps (18) clearly revealed the locations of the metal ions, and the identity of the bound cations became apparent in a density map calculated with the anomalous differences and shifted model phases. The difference in the anomalous scattering between Zn2+ and Ca2+ (f" = 2.29 and 0.52 at 0.933 Å) gave rise to 17.6 and 11.4 sigma  peaks at the two Zn2+ locations (sites II and III; see below) but only to a 5.0 sigma  peak at the Ca2+-binding site. In final refinement rounds, an explicit bulk solvent mask calculated with program XPLOR (19) was introduced into REFMAC. The final model consists of residues 13-131 and 136-188 of SHBG, one molecule of DHT, and one Ca2+ and two Zn2+ ions (Table I). The model also includes 130 solvent molecules and one isopropanol molecule on top of a crystallographic 2-fold axis. The coordinates have been deposited with the Protein Data Bank (accession code 1F5F).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Analysis of zinc-soaked human SHBG crystals

Purification of Human SHBG-- Human SHBG was isolated from shbg4-c transgenic mouse serum (20) as follows: the serum was diluted with an equal volume of 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, and (NH4)2SO4 was added to 10% saturation at 0 °C. After centrifugation for 15 min at 5000 × g, the pellet and floating lipid were discarded. To the supernatant, (NH4)2SO4 was added to 50% saturation at 0 °C. The mixture was centrifuged for 30 min at 10,000 × g, the pellet was redissolved in a minimum volume of water, and the solution was dialyzed overnight at 4 °C against 20 mM Tris-HCl, pH 8.0. The dialyzed solution was centrifuged to remove particulate material, and was loaded onto an fast protein liquid chromatography column packed with 8 ml of anion-exchange resin SOURCE 15Q (Amersham Pharmacia Biotech) and equilibrated with 20 mM Tris-HCl, pH 8.0, containing 1 µM testosterone. Elution was performed using a linear 0-0.25 M NaCl gradient. Fractions containing SHBG were identified using a steroid-binding capacity assay (21) and combined for dialysis prior to a second round of anion-exchange chromatography on a 1-ml SOURCE 15Q fast protein liquid chromatography column. Fractions (0.5 ml) containing SHBG were again combined, concentrated by ultrafiltration through an Ultrafree 15 centrifugal filter device (Millipore), and subjected to gel filtration on a fast protein liquid chromatography column packed with Superdex 75 and equilibrated with 10 mM Tris-HCl, pH 7.0, 1M NaCl, 1 µM testosterone. The fractions containing SHBG were combined for final purification by preparative polyacrylamide gel electrophoresis using a Model 491 Prep Cell (Bio-Rad). The yield of pure SHBG was about 70%, and its physicochemical and steroid-binding properties were similar to those reported for SHBG isolated from human serum using steroid-ligand affinity chromatography (22).

Production and Purification of Human SHBG Mutants-- The amino-terminal G domain (residues 1-205) of human SHBG was produced in Escherichia coli and purified as described earlier (14, 23). Wild-type human SHBG and a H136Q SHBG variant were expressed in Chinese hamster ovary cells (9), and serum-free medium from the cells was concentrated by ultrafiltration through PM-30 membranes (Amicon) with a simultaneous change in buffer to 50 mM Tris-HCl, pH 7.0, 100 mM NaCl, 0.1% NaN3.

Steroid-binding Activity Measurements-- A conventional steroid-binding assay using [3H]DHT as the labeled ligand (21) was modified to assess SHBG steroid-ligand interactions in the absence or presence of Zn2+ or other divalent cations. To avoid formation of insoluble phosphates, 50 mM Tris-HCl, 100 mM NaCl, 1 mM CaCl2 containing 0.1 mg/ml gelatin and 0.1% NaN3 was used as the assay buffer. Equilibrium-binding parameters of SHBG and its mutants were determined by Scatchard analysis (24), and their binding affinities for testosterone or estradiol were assessed relative to DHT, as described previously (21). The steroid-binding properties of SHBG and its mutants were studied after incubation (10 min at room temperature) with various concentrations of different metal (II) chlorides. These steroid-binding assays were performed in the presence of the same salt at a three times lower concentration.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Location of Two Zinc-binding Sites within the Amino-terminal G Domain of Human SHBG-- Three different heavy atom-binding sites can be identified in the 1.7-Å structure of zinc-soaked crystals of the amino-terminal G domain of SHBG (Fig. 1). Site I is occupied by a calcium ion and is located on the rim of the beta -sheet sandwich at the side opposite to the steroid-binding pocket. The Ca2+ is coordinated by seven oxygen atoms forming a pentagonal bipyramid. Two oxygen atoms are provided by the carboxylate group of Asp50, and the carbonyl groups of Glu52 and Ala160 provide two additional oxygen atoms. The remaining oxygen atoms are from three water molecules. This site is identical to the previously described Ca2+-binding site in SHBG (10).


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 1.   Metal-binding sites in the amino-terminal G domain of SHBG. Of the 205 residues of SHBG crystallized, residues 13-131 and 136-188 are visible in the electron density. The steroid DHT is in a ball and stick representation, whereas the calcium-binding site (site I) and the zinc-bindings sites (sites II and III) are shown by white and black spheres, respectively. The figure was prepared with the program MOLSCRIPT (36).

Site II is in close proximity to the steroid ligand and is occupied by zinc (Fig. 2A). Zinc is coordinated by two nitrogen atoms provided by the side chains of His83 and His136 and two oxygens from the carboxylate group of Asp65. The coordination shell of the zinc ion appears uneven and incomplete. This suggests that an additional atom, such as the oxygen atom of a solvent molecule, could attach to the zinc ion. Asp65 and His83 are located on two adjacent beta -strands; Asp65 is at the beginning of strand beta 5 and His83 is at the end of strand beta 6. His136 is the first residue visible in the electron density following the break in the chain trace after residue 131. Residues 130 and 131 were not part of the previously published SHBG structure (10). In the zinc-soaked crystals, the phylogenetically conserved Leu131 (1) is associated with high thermal displacement factors; it packs in between the side chains of Met107 and Met139 and points toward the hydrophobic portion of the steroid.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 2.   Stereo representation of the Sigmaa-weighted 2Fo-Fc electron density map (18) at metal-binding site II of the amino-terminal G domain of SHBG in the presence of zinc contoured at 1.5 sigma  (A). A partially occupied metal-binding site II in the amino-terminal G domain structure of human SHBG (B), as obtained previously at 1.55 Å resolution (10) is shown. Only electron density within 2.5 Å of the atomic positions is displayed in A.

In the original crystal structure of the amino-terminal G domain of human SHBG (10), we observed a strong density at site II. Local disorder, and the existence of alternative conformations for the side chains of Asp65 and His83, hinted that this site was only partially occupied in the crystals, and this prohibited the unambiguous identification of the bound metal ion (Fig. 2B). In the zinc-soaked crystals, no disorder is apparent at this position. The height of the crystallographic anomalous signal, as well as the nature of the coordinating ligands, clearly identifies this site as being occupied by zinc. As expected, the refined thermal displacement factor of the site II Zn2+ ion (40.2 Å2) is comparable to those of the coordinating atoms (43.4 Å2 on average).

Metal-binding site III is formed by the side chain of His101 from the intersheet crossing segment beta 7 to beta 8 and the carboxylate group of Asp117 from the loop segment connecting strand beta 9 to beta 10 (Fig. 1). In the previously published SHBG structure, a 2.7 Å salt bridge is formed between these residues. Upon zinc binding, and as visible in the anomalous density map, zinc intercalates between the two side chains and increases the distance between the functional groups to 3.7 Å. Two additional solvent molecules participate in the distorted tetrahedral coordination of the zinc ion. Of all three metal-binding sites, site III is closest to the proposed dimer interface (10).

Effect of Metal Ions on Human SHBG Steroid-binding Specificity-- To investigate the effect of metal ions on the steroid-binding properties of SHBG, the purified protein was preincubated for 10 min at room temperature with various metal chlorides (as listed in Table II) at a 1 mM concentration prior to performing a [3H]DHT-binding assay. None of the cations influenced DHT binding to SHBG, but zinc and two chemically related metals, cadmium and mercury, inhibited the ability of estradiol to compete with the labeled ligand for the SHBG steroid-binding site (Table II). An independent experiment, in which [3H]estradiol was used as a tracer, confirmed that 1 mM zinc greatly reduces the affinity of SHBG for this estrogen (data not shown). A more detailed analysis (Fig. 3) revealed that the inhibitory effect of zinc on estradiol binding to SHBG could be detected at 10 µM ZnCl2 and increases progressively with increasing ZnCl2 concentrations. Similar effects of cadmium and mercury appeared at higher concentrations (100 µM to 1 mM) and were less pronounced (Fig. 3).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Influence of various divalent cations on the steroid-binding specificity of human SHBG
The ability of estradiol to compete with [3H]DHT for the SHBG steroid-binding site was assessed in the absence (-) or presence of 1 mM metal (II) chlorides, and expressed as B/B0, i.e., a ratio of the amounts of [3H]DHT bound to SHBG in the presence (B) or absence (B0) of 1 µM estradiol. The results are the means of data obtained in two experiments; only Zn2+, Cd2+, and Hg2+ consistently inhibited the ability of estradiol to compete with [3H]DHT.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Concentration dependence of the effect of divalent zinc, cadmium, and mercury ions on steroid binding to SHBG. Specific binding of [3H]DHT was measured at 0 °C in the absence (open symbols) or presence (solid symbols) of 1 µM estradiol after preincubation of SHBG with different concentrations of ZnCl2 (circles), CdCl2 (squares), or HgCl2 (triangles) in the medium.

Analysis of dose-response curves for DHT, testosterone, and estradiol competition of [3H]DHT binding to purified SHBG (Fig. 4) further confirmed that the SHBG affinity for androgens was not influenced by zinc, whereas that for estradiol decreased ~6-fold. Similar results were obtained for SHBG in diluted human pregnancy serum, and in this case 1 mM ZnCl2 caused a 3.5-fold reduction in the SHBG affinity for estradiol.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of zinc on the competition of androgens and estrogen for the binding of [3H]DHT to purified SHBG. Dose-response curves for the competition of DHT (squares), testosterone (circles), and estradiol (triangles) with [3H]DHT for the binding to SHBG at 0 °C with (open symbols, dashed lines) or without (solid symbols and lines) preincubation in the presence of 1 mM ZnCl2.

As described above, our crystallography data revealed two zinc-binding sites within the amino-terminal G domain of human SHBG. Although this domain seems to contain all the amino acids involved in steroid binding (10), the inhibitory effect of zinc on estradiol binding to SHBG might be mediated by additional metal-coordinating sites in the C-terminal G domain of SHBG via long distance conformational rearrangements. However, we observed that the inhibitory effect of zinc on estrogen binding to the amino-terminal G domain of human SHBG is even more pronounced and can be detected at submicromolar concentrations (Fig. 5). Moreover, very low concentrations of zinc (1-10 nM) produced a slight beneficial effect on both androgen and estrogen binding to this isolated domain (data not shown), presumably through stabilization of its structure. On the other hand, high concentrations of zinc (0.1-1 mM) may destabilize this truncated protein as evidenced by a slight decrease in DHT binding (Fig. 5). Nevertheless, competition data (Table III) show unequivocally that increasing ZnCl2 concentrations from 10 nM to 500 µM alters the steroid-binding specificity of the amino-terminal G domain of human SHBG, i.e. its relative binding affinity for estradiol was approximately five times lower at the highest ZnCl2 concentration, whereas that for testosterone was increased 1.5-fold.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 5.   Concentration dependence of the zinc effect on steroid binding to the amino-terminal G domain of human SHBG. Specific binding of [3H]DHT to the amino-terminal G domain of human SHBG (amino acid residues 1-205) was determined in the absence (open circles) or presence (solid circles) of 1 µM estradiol after preincubation of SHBG with different concentrations of ZnCl2.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Influence of zinc on the binding of androgens and estradiol to the amino-terminal G domain of human SHBG
Dose-response curves were generated for the competition of DHT, testosterone, and estradiol with [3H]DHT (~ 2 nM) for binding to the amino-terminal G domain of human SHBG produced in E. coli. The competitive binding assay was performed at 0 °C after preincubation of the protein with various concentrations of ZnCl2, as indicated.

Identification of the Zinc-binding Site that Influences the Steroid-binding Specificity of SHBG-- Expression of wild type human SHBG and a H136Q human SHBG variant (9) allowed us to ascertain which of the two zinc-binding sites identified in the crystal structure has the ability to alter the steroid-binding specificity of human SHBG. The steroid-binding specificity of human SHBG produced by Chinese hamster ovary cells was affected by zinc in almost exactly the same way as SHBG in human serum, i.e. there was an ~5-fold reduction in affinity for estradiol in the presence of 1 mM ZnCl2, whereas the ability of estradiol to displace [3H]DHT from the H136Q SHBG variant (9) was not influenced by zinc at all. Furthermore, sheep SHBG also contains a Gln instead of His at position 136 (1), and analysis of purified sheep SHBG indicated that zinc has no effect on its steroid-binding specificity (data not shown).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have identified three binding sites for metal ions in the amino-terminal G domain of human SHBG. Site I binds calcium, whereas sites II and III bind zinc. The bound metal ion in each site can be identified unambiguously based on the geometry and nature of the coordinating atoms, as well as the height of the anomalous signal in the electron density map. Based on the present data, and a previous estimate that each SHBG subunit contains two potential calcium-binding sites (7), the carboxyl-terminal G domain of human SHBG probably also contains a calcium-binding site, which seems to be a recurring feature of laminin G-like domain structures (25).

It is known that Ca2+ stabilizes the steroid-binding properties of purified SHBG (8), and Ca2+ and Zn2+ promote SHBG dimer formation (9). Of all three metal sites, site III is closest to the proposed dimer interface formed by residues from strands beta 7 and beta 10 (10). This site might therefore be responsible for the stabilization of dimer formation, but the changes observed in the presence or absence of zinc in the vicinity of site III are minor and are limited to a widening of the salt bridge between His101 and Asp117. Therefore, we conclude that the zinc effect on dimer formation is the result of an overall stabilization of the monomer, rather than allosteric rearrangements or an immediate involvement of zinc at the dimer interface.

In a number of zinc-containing proteins, such as carboxypeptidase A, carboanhydrase, and alkaline phosphatase, Zn2+ can be substituted with Hg2+, Cd2+, Cu2+, Ni2+, and Co2+, but in most cases this abolishes enzyme activity (26). In the case of SHBG, alterations in its affinity for specific steroids are only brought about by a limited group of chemically related metal ions. Moreover, whereas the steroid-binding specificity of SHBG is influenced within a biologically meaningful range of zinc concentrations, these other metals were only effective at levels that are toxic. In this context, although serum concentrations of zinc are only in the µM (10-5 M) range, they reach mM concentrations in some biological fluids, such as human seminal plasma (27), and are similarly elevated in human prostate tissues (28). The ability of zinc to alter the steroid-binding properties of SHBG was observed in diluted serum, as well as in highly purified SHBG. The zinc-binding site responsible for this must therefore have a high enough affinity to compete with various plasma zinc-binding proteins (29).

Our studies of an SHBG deletion mutant confirm that the zinc effect on SHBG steroid-binding specificity is mediated by metal-binding sites in its amino-terminal G domain. To identify which of the two zinc-binding sites in this domain is responsible for alterations in steroid-binding specificity, we used an SHBG variant in which the His at position 136 is substituted with Gln (9). This substitution was chosen because it has a minor effect on the steroid-binding specificity of SHBG (9), and because the crystallography data indicated that His136 plays a key role in coordinating zinc in site II. Our data clearly indicate that this substitution eliminates the zinc-induced reduction in SHBG affinity for estradiol and lead us to conclude that zinc exerts its effect on the steroid-binding specificity of SHBG via metal-binding site II. We propose that this can be explained by the following mechanism. In the absence of zinc, Asp65 participates in steroid binding by making a hydrogen bond with the oxygen atom of the hydroxy group at C17 of the steroid, and the side chain of Asp65 is further held in place by a hydrogen bond to the side chain of Thr60 (Fig. 6). Upon zinc binding, this network of hydrogen bonds becomes disrupted because the side chain of Asp65 now turns outwards and participates together with His83 and His136 in zinc binding. A slight displacement of the side chain of Thr60 also takes place, whereas the hydrogen bond between Asn82 and the hydroxyl-group at C17 of DHT remains remarkably unaffected. This is because an almost identical length is observed for this hydrogen bond, namely 2.93 and 2.89 Å, in both structures (Fig. 6). However, these changes in hydrogen bonding of the steroid only affect the affinity of SHBG for estradiol. This indicates that the relative importance of the hydrogen bonds between Asn82 and Asp65 and the hydroxy group at C17 of the steroid molecule differs markedly between C18 and C19 steroid hormones and might be because of small differences in steroid orientation in the binding pocket caused by the absence of the C19 methyl group and/or the aromatic nature of ring A in estradiol. Although this is a reasonable assumption, it needs to be confirmed by further crystallographic analysis of the SHBG steroid-binding site in association with estradiol.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   Proposed structural rearrangements in the proximity of the steroid-binding site of human SHBG in the presence (A) and absence (B) of Zn2+ in metal-binding site II. The model of the unoccupied metal-binding site II (B) is based on a subtraction of the unambiguous conformations observed for Asp65 and His83 in the presence of zinc (A) from the alternative conformations of these residues observed when metal-binding site II was partially occupied (see Fig. 2B). Note that neither the crystallographic analysis nor the hydrogen bonding network in which Asn82 participates allow us to distinguish whether its nitrogen or oxygen atom points toward the steroid 17beta -hydroxy group.

The geometry of the zinc-binding site II is very similar to the zinc-binding site in carboxypeptidase A (26) except that glutamic acid is replaced by aspartic acid in the case of SHBG. This is intriguing because when the amino-terminal G domain of human SHBG is expressed as a glutathione S-transferase fusion protein and purified, it undergoes proteolysis and release from its fusion partner upon storage (23). It is not known whether this phenomenon has biological relevance, but the first 12 residues of the purified amino-terminal G domain of SHBG used for crystallography are also lost during storage,2 and are presumably removed by proteolysis.

Several different crystal structures of proteins containing G domains with a very similar fold have been published recently (10, 30, 31). It is interesting that protein-protein interaction sites mapped onto the surface of individual G domains coincide with the steroid-binding region of SHBG. In addition, a Ca2+ ion is bound in laminin G5 at a position that is virtually identical to site II of SHBG, and it has been proposed that this is responsible for the calcium dependence of laminin binding to dystroglycan (31). In light of what appears to be a conserved multifunctional interaction site in these G domains and the rather complex mechanism revealed here for the modulation of the steroid-binding specificity of SHBG by Zn2+, this region may also be involved in the interaction between SHBG and proteins on the surface of some cells (6).

The histidine at position 136, which plays an important role in coordinating zinc in the metal-binding site II, is not conserved in SHBG molecules from a variety of other mammalian species (1). In addition, it is located in a poorly conserved region that spans the disordered loop structure over the steroid-binding site in our human SHBG crystal structures. Sheep SHBG not only lacks a histidine in this region but has an N-glycosylation site that is utilized at a position corresponding to Ser133 in human SHBG (1). However, when compared with SHBG from many other subprimate species, sheep SHBG has a relatively high affinity for estradiol, which is not influenced by the presence of zinc. In contrast, rabbit SHBG and rodent ABPs contain a histidine residue within this region, and it remains to be seen whether their steroid-binding properties are also influenced by the presence of zinc. Species-specific effects of zinc on endocrine functions are not without precedent. For example, the binding of human growth hormone to the prolactin receptor is increased remarkably in the presence of zinc (32). As shown by mutational and structural studies, the His18, which participates in zinc binding to human growth hormone is conserved only in primates (33), and this explains why growth hormone is not lactogenic in nonprimate species (32, 33).

Even if the zinc-dependent alteration in the steroid-binding specificity of human SHBG is not conserved in other mammalian species, it may serve some specialized function in human tissues where zinc concentrations are high and where SHBG is sequestered from the blood circulation, such as the prostate stroma (12, 13). In this regard, benign prostatic hyperplasia in humans is associated with an excessive activity of sex steroids and/or an imbalance in their relative activities in the stromal compartment of the prostate (34). It remains to be defined how sex steroids are linked to the genesis of this disease but the levels of estradiol are abnormally high in hyperplastic human prostate stroma (35), and this may in some way be related to a local alteration in the binding affinity of SHBG for estradiol versus androgens.

    ACKNOWLEDGEMENTS

We thank Irina Grishkovskaya for crystals of SHBG, David Dales and Maria Catalano for assistance in the production of SHBG mutants, Heather Hodgert-Jury for the transgenic mouse blood, Ed Mitchell from the European Synchrotron Radiation Facility for help with data collection, Udo Heinemann from the Max-Delbrück Center for generous support, and Denise Power for secretarial help.

    FOOTNOTES

* This work was supported by grants from the Medical Research Council of Canada and the Deutsche Forschungsgemeinschaft.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and the structure factors (code 1F5F) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

To whom correspondence should be addressed: London Regional Cancer Centre, 790 Commissioners Rd. East, London, Ontario N6A 4L6, Canada. Tel.: 519-685-8617; Fax: 519-685-8616; E-mail: ghammond@julian.uwo.ca.

Published, JBC Papers in Press, June 19, 2000, DOI 10.1074/jbc.M004484200

2 G. V. Avvakumov and G. L. Hammond, unpublished data.

    ABBREVIATIONS

The abbreviations used are: SHBG, sex hormone-binding globulin; ABP, androgen-binding protein; DHT, 5alpha -dihydrotestosterone.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hammond, G. L. (1993) in Steroid Hormone Action: Frontiers in Molecular Biology (Parker, M. G., ed) , pp. 1-25, IRL Press at Oxford University, Oxford
2. Siiteri, P. K., Murai, J. T., Hammond, G. L., Nisker, J. A., Raymoure, W. J., and Kuhn, R. W. (1982) Recent Prog. Horm. Res. 38, 457-510
3. Joseph, D. R. (1994) Vitam. Horm. 49, 197-280
4. Joseph, D. R., and Baker, M. E. (1992) FASEB J. 6, 2477-2481
5. Mark, M. R., Chen, J., Hammonds, G., Sadick, M., and Godowski, P. J. (1996) J. Biol. Chem. 271, 9785-9789
6. Rosner, W., Hryb, D. J., Khan, M. S., Nakhla, A. M., and Romas, N. A. (1991) J. Steroid Biochem. Mol. Biol. 40, 813-820
7. Ross, J. B. A., Contino, P. B., Lulka, M. F., and Petra, P. H. (1985) J. Protein Chem. 4, 299-304
8. Rosner, W., Toppel, S., and Smith, R. N. (1974) Biochim. Biophys. Acta 351, 92-98
9. Bocchinfuso, W. P., and Hammond, G. L. (1994) Biochemistry 33, 10622-10629
10. Grishkovskaya, I., Avvakumov, G. V., Sklenar, G., Dales, D., Hammond, G. L., and Muller, Y. A. (2000) EMBO J. 19, 504-512
11. Namkung, P. C., Kumar, S., Walsh, K. A., and Petra, P. H. (1990) J. Biol. Chem. 265, 18345-18350
12. Lahtonen, R. (1985) Prostate 6, 177-183
13. Cowan, R. A., Cowan, S. K., Giles, C. A., and Grant, J. K. (1976) J. Endocrinol. 71, 121-131
14. Grishkovskaya, I., Sklenar, G., Avvakumov, G. V., Dales, D., Behlke, J., Hammond, G. L., and Muller, Y. A. (1999) Acta Crystallogr. Sec. D 55, 2053-2055
15. Kabsch, W. (1988) J. Appl. Crystallogr. 21, 916-924
16. Jones, T. A., Zou, J.-Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. Sec. A 47, 110-119
17. CCP4. (1994) Acta Crystallogr. Sec. D 50, 760-763
18. Read, R. J. (1986) Acta Crystallogr. Sec. A 42, 140-149
19. Brünger, A. T., Kuriyan, J., and Karplus, M. (1987) Science 235, 458-460
20. Jänne, M., Deol, H. K., Power, S. G. A., Yee, S.-P., and Hammond, G. L. (1998) Mol. Endocrinol. 12, 123-136
21. Hammond, G. L., and Lähteenmäki, P. L. A. (1983) Clin. Chim. Acta 132, 101-110
22. Hammond, G. L., Robinson, P. A., Sugino, H., Ward, D. N., and Finne, J. (1986) J. Steroid Biochem. 24, 815-824
23. Hildebrand, C., Bocchinfuso, W. P., Dales, D., and Hammond, G. L. (1995) Biochemistry 34, 3231-3238
24. Scatchard, G. (1949) Ann. N. Y. Acad. Sci. 51, 660-672
25. Tisi, D., Talts, J. F., Timpl, R., and Hohenester, E. (2000) EMBO J. 19, 1432-1440
26. Bertini, I., and Luchinat, C. (1994) in Bioinorganic Chemistry (Bertini, I. , Gray, H. B. , Lippard, S. J. , and Valentine, J. S., eds) , pp. 37-106, University Science Books, Mill Valley, California
27. Chia, S. E., Ong, C. N., Chua, L. H., Ho, L. M., and Tay, S. K. (2000) J. Androl. 21, 53-57
28. Habib, F. K., Hammond, G. L., Lee, I. R., Dawson, J. B., Mason, M. K., Smith, P. H., and Stitch, S. R. (1976) J. Endocrinol. 71, 133-141
29. Harris, W. R., and Keen, C. (1989) J. Nutr. 119, 1677-1682
30. Rudenko, G., Nguyen, T., Chelliah, Y., Südhof, T. C., and Deisenhofer, J. (1999) Cell 99, 93-101
31. Hohenester, E., Tisi, D., Talts, J. F., and Timpl, R. (1999) Mol. Cell 4, 783-792
32. Cunningham, B. C., Bass, S., Fuh, G., and Wells, J. A. (1990) Science 250, 1709-1712
33. Somers, W., Ultsch, M., De Vos, A. M., and Kosslakoff, A. A. (1994) Nature 372, 478-481
34. Aarnisalo, P., Santti, H., Poukka, H., Palvimo, J. J., and Jänne, O. A. (1999) Endocrinology 140, 3097-3105
35. Krieg, M., Nass, R., and Tunn, S. (1993) J. Clin. Endocrinol. Metab. 77, 375-381
36. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
V.-M. Leppanen, H. Tossavainen, P. Permi, L. Lehtio, G. Ronnholm, A. Goldman, I. Kilpelainen, and T. Pihlajamaa
Crystal Structure of the N-terminal NC4 Domain of Collagen IX, a Zinc Binding Member of the Laminin-Neurexin-Sex Hormone Binding Globulin (LNS) Domain Family
J. Biol. Chem., August 10, 2007; 282(32): 23219 - 23230.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K.-M. Ng, M. G. Catalano, T. Pinos, D. M. Selva, G. V. Avvakumov, F. Munell, and G. L. Hammond
Evidence That Fibulin Family Members Contribute to the Steroid-dependent Extravascular Sequestration of Sex Hormone-binding Globulin
J. Biol. Chem., June 9, 2006; 281(23): 15853 - 15861.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. V. Avvakumov, I. Grishkovskaya, Y. A. Muller, and G. L. Hammond
Crystal Structure of Human Sex Hormone-binding Globulin in Complex with 2-Methoxyestradiol Reveals the Molecular Basis for High Affinity Interactions with C-2 Derivatives of Estradiol
J. Biol. Chem., November 15, 2002; 277(47): 45219 - 45225.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. M. Selva, K. N. Hogeveen, K. Seguchi, F. Tekpetey, and G. L. Hammond
A Human Sex Hormone-binding Globulin Isoform Accumulates in the Acrosome during Spermatogenesis
J. Biol. Chem., November 15, 2002; 277(47): 45291 - 45298.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Grishkovskaya, G. V. Avvakumov, G. L. Hammond, M. G. Catalano, and Y. A. Muller
Steroid Ligands Bind Human Sex Hormone-binding Globulin in Specific Orientations and Produce Distinct Changes in Protein Conformation
J. Biol. Chem., August 23, 2002; 277(35): 32086 - 32093.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/34/25920    most recent
M004484200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Avvakumov, G. V.
Right arrow Articles by Hammond, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avvakumov, G. V.
Right arrow Articles by Hammond, G. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.